Ancient Proteins Resurrected to Fight Drug-Resistant Superbugs

In a discovery that sounds like the plot of a science fiction thriller, researchers at the University of Oregon have resurrected prehistoric proteins dating back 160 million years and found that some of them can kill drug-resistant bacteria more effectively than modern alternatives. The findings, published in PLOS Biology in August 2026, open an entirely new front in the global battle against antibiotic resistance, one of the most urgent public health crises of our time.

The Antibiotic Resistance Crisis

Antibiotic resistance has been quietly accelerating for decades. The World Health Organization estimates that drug-resistant infections claim hundreds of thousands of lives each year, and without intervention, that number could dwarf cancer deaths by 2050. Bacteria evolve resistance faster than pharmaceutical companies can develop new drugs, creating a dangerous gap between the weapons we have and the threats we face.

Every time a new antibiotic is introduced, bacteria begin adapting to survive it. MRSA, multidrug-resistant tuberculosis, and carbapenem-resistant enterobacteria are just a few examples of pathogens that have rendered once-powerful antibiotics useless. The pipeline for new antibiotics has slowed to a trickle, in part because the economics of antibiotic development are unfavorable for pharmaceutical companies. A drug that cures an infection in days generates far less revenue than one taken daily for years.

This is why the University of Oregon team, led by evolutionary biologist Matt Barber, took a radically different approach. Instead of searching for new compounds in soil samples or deep-sea vents, they looked backward through evolutionary time.

Resurrecting Ancient Lactoferrin

The protein at the center of the investigation is lactoferrin, a molecule found in breast milk, tears, and saliva. Lactoferrin plays multiple roles in the immune system, including sequestering iron that bacteria need to grow. But it also contains an embedded antimicrobial peptide called lactoferricin, which can punch holes in bacterial cell walls and cause them to rupture.

What makes lactoferrin evolutionarily intriguing is that none of its close protein relatives possess this bacteria-killing ability. The antimicrobial property appeared at some point after lactoferrin emerged in the mammalian lineage, roughly 160 million years ago near the end of the Jurassic Period. The researchers wanted to understand when and how this property evolved.

To answer that question, researcher preethi Sil compared the gene sequences of lactoferrin in present-day organisms such as humans and cows. By mapping their evolutionary relationships, she statistically inferred the most likely sequences of their common ancestors, reaching back approximately 160 million years. The team then synthesized the predicted genes and regenerated the ancient proteins in laboratory cells.

Testing Against Deadly Pathogens

The researchers tested the resurrected peptides against several pathogens associated with human diseases, including Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli, and Streptococcus agalactiae. These bacteria are responsible for a wide range of infections, from hospital-acquired pneumonia to sepsis, and many strains have developed significant resistance to standard antibiotics.

The results were striking. The earliest resurrected antimicrobial peptides, dating to the emergence of lactoferrin in ancient mammals, showed modest activity. They disturbed bacterial membranes, but the pathogens were often able to repair the damage and tolerate the peptide. However, peptides from later mammalian ancestors, just a few million years old, displayed progressively stronger antimicrobial activity. In some cases, these ancestral peptides outperformed the modern human versions.

The researchers traced much of this increased potency to a remarkably small structural change. A single amino acid substitution, replacing another amino acid with arginine at a key position, was enough to make the antimicrobial peptide substantially more effective. This finding underscores how tiny genetic changes can have outsized functional consequences.

Evolution as a Billions-Year-Old Experiment

The philosophical implications of the study are as fascinating as the practical ones. As Barber put it, evolution is essentially a billions-year-old science experiment. Every organism alive today is the result of countless rounds of trial and error, with nature selecting for traits that worked and discarding those that did not. By reading the evolutionary record, scientists can recover solutions that nature already tested and validated over geological timescales.

This approach, known as ancestral protein resurrection, has been used in other fields to study enzyme evolution and protein stability. But applying it to antimicrobial discovery is relatively new. The logic is compelling: bacteria and the immune systems that fight them have been locked in an evolutionary arms race for hundreds of millions of years. The weapons that emerged from that conflict are battle-tested in ways that no laboratory screen can replicate.

From Laboratory to Pharmacy

Translating these findings into clinical treatments will require significant additional work. Antimicrobial peptides face challenges as drugs: they can be degraded by enzymes in the body, may trigger immune reactions, and often need to be delivered directly to the site of infection. However, the structural insights from the study could guide the design of synthetic peptides that overcome these limitations.

The researchers are optimistic that their approach can complement existing drug discovery pipelines. By understanding how antimicrobial peptides evolved and how pathogens develop resistance to them, scientists can design combination treatments that are more durable. Barber noted that even if bacteria eventually develop resistance to new antimicrobial peptides, understanding the evolutionary dynamics of that resistance can help scientists anticipate and counter it.

Broader Implications for Global Health

The stakes could not be higher. A 2024 analysis by The Lancet estimated that bacterial antimicrobial resistance was directly responsible for over one million deaths globally in 2019, and associated with nearly five million more. The problem is particularly acute in low- and middle-income countries, where surveillance systems are weaker and access to newer antibiotics is limited.

Several factors are driving the crisis. Overuse of antibiotics in human medicine and agriculture accelerates the evolution of resistance. Climate change is expanding the geographic range of many pathogens. And the COVID-19 pandemic demonstrated how quickly healthcare systems can be overwhelmed by an infectious disease threat.

In this context, novel approaches like ancestral protein resurrection are not curiosities but necessities. The traditional model of antibiotic discovery, which relies on screening soil bacteria for natural products, has been largely exhausted. Most clinically useful antibiotics introduced in recent decades are derivatives of compounds discovered decades ago. Entirely new structural classes are desperately needed.

What Comes Next

The University of Oregon team plans to expand their approach to other antimicrobial proteins in the mammalian immune repertoire. They are also collaborating with structural biologists to understand precisely how the ancestral peptides interact with bacterial membranes at the molecular level. This knowledge could enable rational design of peptides with enhanced potency and stability.

Other research groups are exploring complementary strategies. Bacteriophage therapy, which uses viruses that specifically target bacteria, has shown promise in treating multidrug-resistant infections. CRISPR-based approaches that selectively destroy resistance genes are another active area of investigation. The hope is that these diverse approaches can be combined into multipronged treatment strategies that make it far harder for bacteria to evolve resistance.

A Message for Everyday Health

While ancestral protein resurrection may seem distant from daily life, it carries an important message for everyone. The immune system that protects you is the product of hundreds of millions of years of evolutionary refinement. The proteins in your tears, saliva, and breast milk are not random molecules but precision-engineered weapons honed by countless generations of natural selection.

Supporting that immune system through adequate sleep, a diverse diet rich in fiber, regular physical activity, and stress management is not vague lifestyle advice. It is evidence-based maintenance of biological machinery that has been optimized since the age of dinosaurs. And as scientists continue to mine the evolutionary record for new medical tools, the connection between deep time and modern medicine will only grow stronger.

The next breakthrough antibiotic may not come from a pharmaceutical laboratory or a tropical rainforest. It may come from a protein that guarded the health of a tiny Jurassic mammal, 160 million years before the first human walked the Earth. In the fight against superbugs, the past may hold the key to the future.

---

Edited by Palawan @QUE.COM
Website: https://QUE.COM Intelligence
Sponsored by: https://MAJ.COM AI Autonomous